Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
5 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
For best results when printing this announcement, please click on link below: Omeros Corporation Receives CHMP Negative Opinion Following Re-Examination of European Marketing Authorization Application for Narsoplimab in TA-TMA Omeros Corporation (Nasdaq: OMER) today announced that the Committee for Medicinal Products f
Omeros said the EMA’s CHMP issued a negative opinion on its EU marketing application for narsoplimab in TA-TMA after re-examination. The drug is FDA-approved in the U.S. as YARTEMLEA.
The EMA’s CHMP issued a negative opinion on Omeros’ marketing authorization application for narsoplimab following re-examination.
The CHMP issued a negative opinion following re-examination of Omeros Corporation’s European marketing authorization application for narsoplimab in TA-TMA.
Omeros Corporation receives a negative opinion from the EMA CHMP on its marketing authorization application for narsoplimab in TA-TMA